This is the place for emergency medicine’ features real people working in emergency departments in Coventry and Manchester. Commissioned by the Royal College of Emergency Medicine (RCEM), the film is a snapshot of life in A&E – ‘where excellence is…
Will Forte Partners with Teva to Launch “Honestly HD”—A Candid Conversation About Huntington’s Disease Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a partnership with actor, comedian and advocate, Will Forte, to…
Neurocrine Biosciences Launches Phase 2 Trial of NBI-1065890 for Tardive Dyskinesia in Adults Neurocrine Biosciences, Inc. today announced the initiation of its Phase 2 clinical study of investigational compound NBI-1065890 in adults with tardive dyskinesia (TD). NBI-1065890 is a next-generation,…
WuXi Biologics and HanchorBio Forge Strategic Partnership to Advance Next-Gen Bi- and Multi-Functional Fusion Proteins WuXi Biologics, a global leading Contract Research, Development and Manufacturing Organization (CRDMO), and HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies…
Trelegy Ellipta Gains Approval in China for Adults with Uncontrolled Asthma GSK plc today announced that China’s National Medical Products Administration (NMPA) has approved a new indication for Trelegy Ellipta (fluticasone furoate / umeclidinium / vilanterol ‘FF/UMEC/VI’) for the treatment of patients…
Lilly’s Sacituzumab Govitecan Receives U.S. FDA Breakthrough Therapy Designation for Platinum-Resistant Ovarian Cancer Eli Lilly and Company today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to sofetabart mipitecan (LY4170156) for the treatment of adult patients…
Moderna and Merck Report Five-Year Data Showing Sustained Improvement in Recurrence-Free Survival with Intismeran Autogene Plus KEYTRUDA® in High-Risk Stage III/IV Melanoma Patients After Complete Resection Moderna, Inc. and Merck (NYSE: MRK), known as MSD outside of the United States and…
Shionogi Receives Minister of Health, Labour and Welfare Award for Cefiderocol at the 8th Japan Medical Research and Development Grand Prize Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereinafter, “Shionogi”) announced that it had…
Bayer Applauds U.S. Supreme Court’s Decision to Review Durnell Case in Roundup™ Litigation The U.S. Supreme Court today announced that it will review the Durnell Roundup™ case. Monsanto petitioned the court to hear Durnell in April 2025 and address the split in authority among…
Opdivo® IV Infusion Approved in Taiwan in Combination with Yervoy® for Adults with Unresectable or Metastatic MSI-H/dMMR Colorectal Cancer Ono Pharmaceutical Co., Ltd. today announced that Ono Pharma Taiwan Co., Ltd. (Taipei, Taiwan; “OPTW”), a Taiwanese subsidiary of Ono, received…
Neurocrine Biosciences Presents Head-to-Head Data Showing INGREZZA® (valbenazine) Capsules Achieve Higher VMAT2 Target Occupancy Than AUSTEDO XR Neurocrine Biosciences, Inc. today announced the presentation of the first head-to-head data comparing vesicular monoamine transporter 2 (VMAT2) target occupancy between INGREZZA® (valbenazine) capsules and AUSTEDO XR…
BMS Reports Positive Phase 3 SCOUT-HCM Results for Camzyos in Teens with oHCM Bristol Myers Squibb today announced positive topline results from SCOUT-HCM, a Phase 3 trial evaluating Camzyos (mavacamten) in the first study of a cardiac myosin inhibitor (CMI) in adolescents…